Insider Sell: Denise Devine Sells 4,000 Shares of SelectQuote In
Denise Devine, a Director at SelectQuote Inc (SLQT), sold 4,000 shares of the company on May 19, 2026. Following this transaction, Devine owns 367,214 shares. The stock is currently trading at $1.02, indicating it might be a "Possible Value Trap" according to GuruFocus's GF Value of $2.20.
[Form 4] SelectQuote, Inc. Insider Trading Activity
SelectQuote, Inc. director Denise L. Devine reported an open-market sale of 4,000 shares of common stock on May 19, 2026, at an average price of $1.02 per share. Following this transaction, Devine directly holds 367,214 shares of SelectQuote common stock. This insider trading activity was filed as a Form 4, indicating a net sale of $4,080.
[144] SelectQuote, Inc. SEC Filing
This SEC filing for SelectQuote, Inc. (SLQT) is a Form 144 Notice of Proposed Sale of Securities pursuant to Rule 144. It details the proposed sale of 4000 shares of common stock by an unnamed person through Morgan Stanley Smith Barney LLC on May 19, 2026, with an aggregate market value of $4240.00. The shares were acquired via an open market purchase on May 21, 2020.
SelectQuote Announces Participation in Upcoming RBC Global Healthcare Conference on May 20
SelectQuote, Inc. announced that its CFO, Ryan Clement, and Head of Investor Relations, Matt Gunter, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, at approximately 11:00 am ET. Management will also be available for investor meetings. The company, a leading distributor of Medicare insurance policies and owner of a growing healthcare services platform, will discuss its business and financial updates.
SelectQuote Q3 FY2026 slides: EBITDA surges 18% on Senior strength
SelectQuote (NYSE:SLQT) reported a strong fiscal third quarter of 2026, with adjusted EBITDA surging 18% year-over-year to $45 million and consolidated revenue increasing 6% to $431 million. The company's stock jumped significantly after the earnings release, driven by robust profitability and an impressive 450% earnings surprise in net income per share. The Senior division was a key performer, with its adjusted EBITDA up 28%, alongside significant improvements in operational efficiency and growth in the Healthcare Services segment.
SelectQuote Q3 FY2026 slides: EBITDA surges 18% on Senior strength
SelectQuote (NYSE:SLQT) reported strong Q3 FY2026 earnings, with adjusted EBITDA surging 18% to $45 million on $431 million in revenue. The company's Senior segment was a key driver, achieving an 8% revenue increase and 28% adjusted EBITDA growth, contributing significantly to a 450% earnings surprise. Operational efficiencies, including increased agent productivity and reduced marketing expenses, also played a crucial role in the improved profitability and investor confidence.
Zacks Research Upgrades SelectQuote (NYSE:SLQT) to Strong-Buy
Zacks Research has upgraded SelectQuote (NYSE:SLQT) from a "hold" to a "strong-buy" rating, indicating an improving analyst outlook for the company. Despite mixed analyst ratings, the stock holds a "Moderate Buy" consensus and an average target price of $2.92. SelectQuote recently surpassed quarterly EPS expectations, reporting $0.15 against an anticipated loss of $0.02, though revenue slightly missed estimates.
SelectQuote reaffirms fiscal 2026 outlook of $1.61B-$1.71B revenue and $90M-$100M adjusted EBITDA, while targeting SelectRx $40M-$50M run rate
SelectQuote (NYSE: SLQT) has reaffirmed its financial guidance for fiscal year 2026, projecting revenue between $1.61 billion and $1.71 billion and adjusted EBITDA of $90 million to $100 million. Additionally, the company is targeting a run rate of $40 million to $50 million for its SelectRx segment. This outlook provides investors with an updated long-term financial perspective for the company.
SelectQuote, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:SLQT) 2026-05-07
SelectQuote, Inc. (NYSE:SLQT) published its Q3 2026 earnings call presentation, reporting an EPS of $0.04, beating estimates by $0.02. The company's revenue for the quarter was $430.93M, representing a 5.58% year-over-year increase, but missing analyst estimates by $7.99M. This report provides the slide deck used during the earnings call.
SelectQuote, Inc. (NYSE:SLQT) Given Average Recommendation of "Moderate Buy" by Brokerages
SelectQuote, Inc. (NYSE:SLQT) has an average "Moderate Buy" rating from five analysts, with a 1-year price target of approximately $2.92. Despite revenue slightly missing forecasts, the company reported an EPS beat of $0.15 against estimates of ($0.02). Analyst opinions are varied, with some downgrading and others upgrading the stock, while institutional ownership stands at around 34.6%.
SelectQuote (SLQT) Returns To Quarterly Profit But Volatile EPS Tests Bullish Margin Story
SelectQuote (SLQT) reported a profitable Q2 2026 with total revenue of US$537.1 million and net income of US$51.2 million, translating to basic EPS of US$0.27. While bulls highlight potential for higher EBITDA margins and recurring healthcare revenue, the company's EPS has been volatile with a mix of profits and losses in previous quarters. Analysts forecast a decline in earnings despite a seemingly low P/E ratio, raising concerns about the sustainability of its current profit levels and its ability to cover interest payments.
SelectQuote reaffirms fiscal 2026 outlook of $1.61B-$1.71B revenue and $90M-$100M adjusted EBITDA, while targeting SelectRx $40M-$50M run rate
SelectQuote has reaffirmed its financial outlook for fiscal year 2026, projecting revenue between $1.61 billion and $1.71 billion and adjusted EBITDA of $90 million to $100 million. Additionally, the company is targeting a run rate for its SelectRx segment of $40 million to $50 million. This announcement indicates the company's continued confidence in its long-term financial performance and strategic initiatives.
SelectQuote posts higher Q3 revenue amid Medicare shifts
SelectQuote, Inc. reported increased revenue and net income for the third quarter of fiscal year 2026, driven by operational steadiness despite shifts in the Medicare Advantage and prescription drug markets. The company achieved consolidated revenue of $430.9 million and a net income of $40.2 million, reaffirming its financial outlook for fiscal 2026. Growth was noted in its Senior division and SelectRx pharmacy business, which are positioned for future cash flow expansion.
SelectQuote, Inc. (NYSE:SLQT) Q3 2026 Earnings Call Transcript
SelectQuote, Inc. (NYSE: SLQT) reported strong financial results for Q3 2026, exceeding earnings expectations with an EPS of $0.11 against an expected $-0.02. The company reaffirmed its fiscal 2026 outlook, driven by solid performance across its Senior, Healthcare Services, and Life Insurance segments, and highlighted its success in expanding cash flow and enhancing operational efficiencies. CEO Tim Danker and CFO Ryan Clement discussed strategic initiatives like SelectQuote Local and positive adjustments to commissions receivable, while addressing the disconnect between the company's valuation and its intrinsic value.
SelectQuote (NYSE:SLQT) Stock Forecast & Analyst Predictions
SelectQuote (NYSE:SLQT) is forecast to experience a decline in earnings at 21.5% per annum, despite an expected annual revenue growth of 4.8%. The company recently reaffirmed its earnings guidance for fiscal year 2026, projecting revenue between $1.61 billion and $1.71 billion. Analyst price targets have generally been trimmed, and the stock faces major risks including highly volatile share price, declining earnings forecasts, and a notice of non-compliance with NYSE listing standards due to its average closing price falling below $1.00.
SelectQuote downgraded by Credit Suisse with a new price target
SelectQuote (SLQT) has been downgraded by Credit Suisse, which also set a new price target for the company. This update is part of Credit Suisse's recent analyst ratings on SelectQuote, following other analyst actions earlier in the year. The article also provides recent SEC filings and press releases related to SelectQuote's financial performance and operational updates.
SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2026 Results
SelectQuote, Inc. reported strong third-quarter fiscal year 2026 results, with consolidated revenue reaching $430.9 million and net income climbing to $40.2 million. The company reaffirmed its fiscal year 2026 guidance, expecting revenue between $1.61 billion and $1.71 billion, and Adjusted EBITDA between $90 million and $100 million. CEO Tim Danker highlighted consistent profit and cash flow despite market shifts, driven by operational execution and the growing SelectRx business.
Earnings call transcript: SelectQuote Q3 2026 beats EPS expectations
SelectQuote Inc. (SLQT) reported strong Q3 2026 earnings, beating EPS expectations with $0.11 against a forecast of $0.02, leading to a 21.7% surge in premarket trading despite revenue falling slightly short at $431 million. The company highlighted robust growth in its Senior and Healthcare Services segments and an 18% increase in Adjusted EBITDA, reaffirming its fiscal year 2026 outlook. Management expressed confidence in future cash flow generation and the company's strategic initiatives, including a new "SelectQuote Local" franchise model, while actively addressing the disconnect in its equity valuation.
SelectQuote reports Q3 FY2026 revenue $430.9M, net income $40.2M, Adjusted EBITDA $44.6M
SelectQuote announced its financial results for the third quarter of fiscal year 2026, reporting consolidated revenue of $430.9 million, net income of $40.2 million, and Adjusted EBITDA of $44.6 million. The company reiterated its fiscal 2026 guidance, projecting revenue between $1.61 billion and $1.71 billion and Adjusted EBITDA between $90 million and $100 million. Key highlights included growth in Healthcare Services membership and increased commissions receivable, indicating strong future cash flow potential.
SelectQuote: Fiscal Q3 Earnings Snapshot
SelectQuote, Inc. (SLQT) reported a profit of $40.2 million in its fiscal third quarter, resulting in a net income of 11 cents per share. Adjusted earnings were 15 cents per share, and the company posted revenue of $430.9 million. SelectQuote anticipates full-year revenue to be between $1.61 billion and $1.71 billion.
SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2026 Results
SelectQuote, Inc. (NYSE: SLQT) announced its third-quarter fiscal year 2026 results, reporting consolidated revenue of $430.9 million, net income of $40.2 million, and Adjusted EBITDA of $44.6 million. The company reaffirmed its fiscal year 2026 guidance, expecting revenue between $1.61 billion and $1.71 billion and Adjusted EBITDA between $90 million and $100 million. CEO Tim Danker highlighted consistent profit and cash flow, driven by operational execution and the strong performance of its healthcare services model, noting a high 6.7X revenue to customer acquisition cost multiple.
Q2 2026 SelectQuote Inc Earnings Call Transcript
SelectQuote Inc. (SLQT) reported a strong second quarter for fiscal 2026, with a 12% year-over-year revenue increase to $537 million, primarily driven by strong performance in its senior segment and a 26% revenue increase in Select RX. However, the company lowered its full fiscal year 2026 guidance by $40 million due to marketing budget cuts from a national carrier and changes in PBM reimbursement policies, which are expected to create a $20 million headwind to EBITDA. Despite these challenges, SLQT secured a new $415 million credit facility, improving its capital flexibility and extending debt maturities to 2031, while also maintaining a 33% policyholder recapture rate.
SelectQuote (SLQT) Q2 2025 earnings summary
SelectQuote (SLQT) reported strong Q2 FY25 results with a 19% year-over-year revenue growth to $481.1M and a 30% increase in Adjusted EBITDA to $87.5M, driven by its Senior and Healthcare Services segments. The company raised its FY25 guidance for revenue, Adjusted EBITDA, and net income, reflecting robust operational performance. Strategic financial moves, including a $350M preferred equity investment and a $100M securitization, have improved liquidity and capital structure.
SelectQuote (SLQT) Projected to Post Quarterly Earnings on Tuesday
SelectQuote (SLQT) is projected to announce its Q3 2026 earnings before market open on Tuesday, May 5th, with analysts expecting an EPS of ($0.02) and revenue of $438.93 million. The company beat estimates in the last quarter but analysts now forecast $0 EPS for the current and next fiscal years, assigning a "Hold" rating with a consensus target price of $2.92. Recent trading saw SLQT stock up 7.6% to $0.99, and institutional ownership stands at approximately 34.6%.
Follow the Trend Seeker: Beaten-Down SelectQuote Stock Surges 54% in 1 Month as Barchart’s Data Signals ‘Buy’
SelectQuote (SLQT) stock has surged 54% in the last month after Barchart's Trend Seeker issued a "Buy" signal on April 17, despite a 72% loss over the past year. Analysts project significant earnings growth for next year, though current Wall Street sentiment is mixed. The article suggests SLQT as a speculative rebound candidate for investors looking for beaten-down stocks starting to recover.
SelectQuote Secures New $415 Million Credit Facility Comprised of $325 Million Term Loan with Pathlight Capital Alongside $90 Million Revolving Credit Facility with UMB Bank
SelectQuote, Inc. (NYSE: SLQT) has secured a new $415 million credit facility, consisting of a $325 million term loan from Pathlight Capital and a $90 million revolving credit facility from UMB Bank. This agreement significantly extends their debt maturity to 2031, enhances liquidity, and improves the cost of capital. The company states this financing strengthens its financial position and supports future growth, particularly for its senior health insurance and healthcare services businesses.
SelectQuote (SLQT) Q3 2025 earnings summary
SelectQuote (SLQT) reported Q3 FY2025 revenue of $408.2 million, an 8% increase year-over-year, driven by strong growth in Healthcare Services and SelectRx membership. Net income rose significantly to $26.0 million, though Adjusted EBITDA saw a decline due to margin pressures in the Senior segment. The company also completed a $350 million preferred stock transaction to bolster liquidity and reaffirmed its FY2025 guidance.
SelectQuote (SLQT) Proxy Filing Summary
This article summarizes SelectQuote's (SLQT) proxy filing, detailing the annual meeting scheduled for November 12, 2024. Key voting matters include the election of two Class II directors, ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation. The board recommends approval of all proposals.
SelectQuote (SLQT) Proxy Filing Summary
This article summarizes SelectQuote's (SLQT) proxy filing, detailing the upcoming annual meeting scheduled for November 11, 2025. Key agenda items include the election of two Class III director nominees (Donald L. Hawks III and Denise L. Devine), the ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation. The board of directors recommends voting in favor of all proposed items.
SelectQuote (SLQT) Q1 2025 earnings summary
SelectQuote (SLQT) reported a 26% year-over-year revenue increase to $292.3 million in Q1 FY2025, driven by significant growth in pharmacy services and strong agent productivity, though net loss widened to $44.5 million. The company's Adjusted EBITDA improved to $(1.7) million from $(11.4) million, and SelectRx membership saw a 64% increase. SelectQuote has raised its fiscal 2025 outlook for revenue and Adjusted EBITDA following strong performance in the Medicare Advantage enrollment period.
SelectQuote to Release Fiscal Third Quarter 2026 Earnings on May 5
SelectQuote, Inc. (NYSE: SLQT) announced it will release its fiscal third quarter 2026 financial results before market open on Tuesday, May 5, 2026. CEO Tim Danker and CFO Ryan Clement will host a conference call on the same day at 8:30 AM ET to discuss the results. Interested parties can access the live webcast via the company's investor relations website.
Press Release: SelectQuote to Release Fiscal Third Quarter 2026 Earnings on May 5
SelectQuote, Inc. (NYSE: SLQT) announced it will release its fiscal third quarter 2026 earnings after the market closes on Tuesday, May 5, 2026. Management will host a conference call and webcast the same day at 4:30 PM ET to discuss the results and provide a business update. A replay of the webcast will be available following the call.
SelectQuote to Release Fiscal Third Quarter 2026 Earnings on May 5
SelectQuote, Inc. (NYSE: SLQT) announced that it will release its fiscal third-quarter 2026 financial results on Tuesday, May 5, 2026, before market open. CEO Tim Danker and CFO Ryan Clement will host a conference call at 8:30 am ET on the same day to discuss the results. Interested parties can access the live webcast or register to dial into the conference call via the company's investor relations website.
SelectQuote (SLQT) Q2 2026 earnings summary
SelectQuote (SLQT) reported Q2 FY2026 revenue of $537.1 million, a 12% year-over-year increase, driven by strong growth in Healthcare Services and Life segments. Despite a slight dip in Adjusted EBITDA to $84.7 million due to PBM reimbursement headwinds, net income rose to $69.3 million. The company secured a new $415 million credit facility and revised its fiscal 2026 guidance downwards by $40 million due to external factors.
SelectQuote, Inc. (NYSE:SLQT) Short Interest Up 53.9% in March
SelectQuote, Inc. (NYSE:SLQT) saw a significant increase in short interest during March, rising 53.9% to 4,753,933 shares as of March 31. This represents 3.1% of shares outstanding and a days-to-cover ratio of 4.0. Despite beating quarterly EPS estimates, the stock's market capitalization is $129.4 million with a consensus "Hold" rating and an average price target of $2.92 from analysts.
Bronstein, Gewirtz & Grossman, LLC Encourages SelectQuote, Inc. (SLQT) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing at SelectQuote, Inc. (SLQT). The firm is encouraging shareholders who purchased SelectQuote securities before September 9, 2020, and still hold them, to come forward and assist with the investigation. Bronstein, Gewirtz & Grossman, LLC specializes in securities fraud class actions and shareholder derivative suits, aiming to restore investor capital and ensure corporate accountability.
Bronstein, Gewirtz & Grossman, LLC Is Investigating SelectQuote, Inc. (SLQT) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against SelectQuote, Inc. (NYSE:SLQT) on behalf of investors who purchased securities prior to September 9, 2020, and continue to hold them. The investigation concerns possible corporate wrongdoing by SelectQuote and its officers/directors. The law firm encourages affected shareholders to connect with them for more information and to assist in the investigation.
SelectQuote, Inc. (SLQT) Stock forecasts
This article provides a brief overview of SelectQuote, Inc. (SLQT) stock forecasts, highlighting an Argus quantitative report from June 2022. It mentions SLQT's role as a direct-to-consumer distribution platform for health and life insurance and lists related reports for another company, GTM, from early 2026. The article also includes various market data and other trending financial information.
SLQT PE Ratio & Valuation, Is SLQT Overvalued
SelectQuote Inc (SLQT) is currently in the "Fair zone" with a forward PS ratio of 0.14, which is considered fair compared to its five-year average. The fair price for SLQT is estimated to be between $0.58 and $0.97. Despite a P/S ratio of 0.06, which is above the industry average, its strong revenue growth of 11.65% suggests this premium may be unsustainable.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against SelectQuote, Inc. (SLQT) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by SelectQuote, Inc. (NYSE: SLQT) and its officers/directors. The firm is encouraging shareholders who purchased SelectQuote securities before September 9, 2020, and continue to hold them, to join the investigation. This class action aims to recover investor capital and ensure corporate accountability.
Book value per share of SelectQuote Inc – MUN:6SJA
The article focuses on the book value per share of SelectQuote Inc (MUN:6SJA) listed on the Munich Stock Exchange. It presents a page from TradingView displaying financial information for the company, specifically highlighting its book value per share. The page indicates that the market is closed and provides various data sources.
Bronstein, Gewirtz & Grossman, LLC Encourages SelectQuote, Inc. (SLQT) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of SelectQuote, Inc. (NYSE: SLQT) stockholders who purchased securities prior to September 9, 2020, and continue to hold them. The investigation aims to determine if SelectQuote officers and/or directors engaged in corporate wrongdoing. Investors are encouraged to visit the firm's website or contact them for more information and to assist with the investigation.
SelectQuote (SLQT) price target decreased by 14.04% to 3.12
This article reports a 14.04% decrease in the price target for SelectQuote (SLQT), bringing it down to $3.12. The content provided is minimal, indicating only this change.
SelectQuote Faces NYSE Listing Compliance Challenge Amid Pressure
SelectQuote (SLQT) has received a notice from the NYSE for non-compliance, as its average share price fell below $1 for 30 consecutive trading days. The company has a six-month period to regain compliance, with management prepared to take shareholder-approved measures if necessary. Despite recent strong fiscal second-quarter results and a new $415 million credit facility, the stock faces pressure and analysts rate it a Hold with a $0.71 price target.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against SelectQuote, Inc. (SLQT) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by SelectQuote, Inc. (NYSE: SLQT). The firm is encouraging investors who purchased SelectQuote securities before September 9, 2020, and continue to hold them, to learn more and assist in the investigation. Investors can find additional information or contact the firm to participate.
SelectQuote receives NYSE notice over sub-$1 share price
SelectQuote (NYSE: SLQT) has received a notice from the New York Stock Exchange (NYSE) because its average stock price fell below $1.00 per share over a 30-consecutive trading day period. The company now has six months to regain compliance, which requires its stock to trade above $1.00 for at least 30 consecutive days. SelectQuote is exploring its options to address this non-compliance, including a reverse stock split.
SelectQuote receives NYSE notice over stock price compliance
SelectQuote Inc. (NYSE: SLQT) received a notice from the NYSE due to its common stock trading below $1.00 per share for 30 consecutive trading days. The company has a six-month cure period to regain compliance, needing its stock to close at or above $1.00 with an average closing price of at least $1.00 over the preceding 30 days. Despite the current low stock price and the delisting notice, InvestingPro analysis suggests the stock may be undervalued, and the company recently reported stronger-than-expected Q2 fiscal year 2026 earnings and launched a new franchise model.
SelectQuote Faces NYSE Listing Compliance Challenge Amid Pressure
SelectQuote (SLQT) has received a notice from the NYSE regarding non-compliance, as its average share price dropped below $1 for 30 consecutive trading days. The company has a six-month window to regain compliance, with management planning to leverage strong recent financial results, including a new $415 million credit facility, to support its position. Spark, TipRanks' AI Analyst, rates SLQT as Neutral, citing improving fundamentals and a constructive earnings outlook, but is tempered by weak technicals and inconsistent cash flow.
SelectQuote receives NYSE notice over sub-$1 share price
SelectQuote, an insurance comparison marketplace, announced it received a notice from the New York Stock Exchange due to its stock trading below the minimum $1.00 per share requirement. The company has six months to regain compliance, with a possible extension, by having its common stock's average closing price reach at least $1.00 over a consecutive 30 trading-day period. SelectQuote plans to notify the NYSE of its intention to cure the deficiency.
SelectQuote Disclosed Failure to Satisfy a Continued Listing Rule or Standard
SelectQuote (SLQT) received notice from the NYSE on March 19, 2026, for non-compliance with Section 802.01C due to its average closing price falling below $1.00 for 30 consecutive trading days. The company intends to rectify this deficiency within a six-month period, during which its stock will continue to trade on the NYSE. This information is based on an original SEC Filing (8-K) from March 25, 2026.
